Therapy of the Overactive Bladder Syndrome (TOBS)

C

Cantonal Hospital, Frauenfeld

Status and phase

Completed
Phase 4

Conditions

Overactive Bladder

Treatments

Procedure: PFMT and WBVT
Drug: solifenacin

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT01314781
SOL-OAB-01-08

Details and patient eligibility

About

The aim of the present study is to investigate in patients with overactive bladder syndrome (OABS) whether a combination treatment of solifenacin with pelvic floor muscle training and whole body vibration training achieves a better treatment outcome than a treatment with solifenacin alone.

Full description

The treatment of patients with OAB in clinical practice often consists of drug therapy in combination with bladder training and/or behavioural therapies such as whole body vibration training (WBVT) and pelvic floor muscle training (PFMT). However, very little data exist on the benefits of such combinations. In particular, there are not data on the association of antimuscarinic agents with both WBVT and PFMT. In order to optimize the treatment of OAB it is of great importance to conduct studies which compare pharmacotherapy alone with a combination of pharmacotherapy and behavioural techniques. The aim of the present study is to investigate in patients with OABS whether a combination treatment of solifenacin with pelvic floor muscle training and whole body vibration training achieves a better treatment outcome than a treatment with solifenacin alone. At the baseline visit subjects will be randomised into 2 treatment arms. Patients randomized to group A will receive solifenacin 5mg tablet once daily and a training programme for PFMT and WBVT once a week. Subjects randomised to group B will receive solifenacin 5mg tablet once daily. Efficacy evaluation will take place at week 8 and 16. Safety evaluations will take place at each visit. At week 8, after discussion with the investigator, the patient will have an option to continue with the original dose or request a dose increase based on their satisfaction of efficacy and tolerability.

Enrollment

66 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female patients with symptoms of overactive bladder (urinary frequency and urgency with or without incontinence) for ≥ 3 months
  • Age ≥ 18 years old
  • Urinary frequency ≥ 8 micturitions on average per 24 hours during the 3-day micturition diary period
  • At least 3 episodes of urgency with or without incontinence (≥ 3) during the 3-day micturition diary period
  • Patient provides written informed consent
  • Patient is willing to complete the micturition diary

Exclusion criteria

  • Clinically significant bladder outflow obstruction at risk of urinary retention (at the discretion of the investigator)
  • Significant post void residual volume (> 200ml)
  • Uncontrolled narrow angle glaucoma, urinary or gastric retention, severe ulcerative colitis, toxic megacolon, myasthenia gravis or any other medical condition which in the opinion of the investigator makes the use of anticholinergics contraindicated
  • Neurological cause of abnormal detrusor activity
  • Any clinically significant condition, which in the opinion of the investigator makes the subject unsuitable for the study
  • Current non-drug treatment including pelvic floor muscle and whole body vibration training
  • Known contraindications for whole body vibration training (cardiovascular, neurological or orthopaedic diseases, diabetes, tumor, pacemaker)
  • Pregnant women or women who intend to become pregnant during the study
  • Known or suspected hypersensitivity to solifenacin or lactose
  • Concomitant use of a strong cytochrome P450 3A4 inhibitor (e.g. ketoconazole)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

66 participants in 2 patient groups

solifenacin 5mg, PFMT and WBVT
Experimental group
Description:
Patients randomized to group A will receive solifenacin 5mg tablet once daily and a training programme for PFMT and WBVT once a week.
Treatment:
Drug: solifenacin
Procedure: PFMT and WBVT
solifenacin 5mg
Active Comparator group
Description:
Subjects randomised to group B will receive solifenacin 5mg tablet once daily.
Treatment:
Drug: solifenacin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems